MX2022011591A - Anticuerpos anti-ceramida. - Google Patents

Anticuerpos anti-ceramida.

Info

Publication number
MX2022011591A
MX2022011591A MX2022011591A MX2022011591A MX2022011591A MX 2022011591 A MX2022011591 A MX 2022011591A MX 2022011591 A MX2022011591 A MX 2022011591A MX 2022011591 A MX2022011591 A MX 2022011591A MX 2022011591 A MX2022011591 A MX 2022011591A
Authority
MX
Mexico
Prior art keywords
subject
ceramide antibodies
antigen
need
binding fragments
Prior art date
Application number
MX2022011591A
Other languages
English (en)
Inventor
Richard Kolesnick
Yong Wang
Yinan Wu
Arthur Tinkelenberg
Jordon Kuo- Ming Wang
Raphael Levy
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2022011591A publication Critical patent/MX2022011591A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención proporciona composiciones de anticuerpos anti-ceramida y fragmentos de unión a antígeno de los mismos. La invención proporciona además métodos para prevenir o inhibir la muerte celular en un sujeto que lo necesita, que comprende administrar los anticuerpos anti-ceramida o fragmentos de unión a antígeno a un sujeto. El sujeto que lo necesita puede sufrir de una enfermedad autoinmune, síndrome GI o GvHD.
MX2022011591A 2020-03-18 2021-03-18 Anticuerpos anti-ceramida. MX2022011591A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991232P 2020-03-18 2020-03-18
PCT/US2021/022914 WO2021188770A1 (en) 2020-03-18 2021-03-18 Anti-ceramide antibodies

Publications (1)

Publication Number Publication Date
MX2022011591A true MX2022011591A (es) 2023-03-06

Family

ID=77771401

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011591A MX2022011591A (es) 2020-03-18 2021-03-18 Anticuerpos anti-ceramida.

Country Status (11)

Country Link
US (1) US20230167197A1 (es)
EP (1) EP4121110A1 (es)
JP (1) JP2023534779A (es)
KR (1) KR20230031814A (es)
CN (1) CN115811987A (es)
AU (1) AU2021236669A1 (es)
BR (1) BR112022018682A2 (es)
CA (1) CA3172201A1 (es)
IL (1) IL296550A (es)
MX (1) MX2022011591A (es)
WO (1) WO2021188770A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017002433A2 (pt) 2014-08-07 2017-11-28 Ceram Therapeutics anticorpos anticeramida

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110043786A (ko) * 2008-08-20 2011-04-27 센토코 오르토 바이오테크 인코포레이티드 조작된 항-ｉｌ-13 항체, 조성물, 방법 및 용도
BR112017002433A2 (pt) * 2014-08-07 2017-11-28 Ceram Therapeutics anticorpos anticeramida

Also Published As

Publication number Publication date
CN115811987A (zh) 2023-03-17
IL296550A (en) 2022-11-01
US20230167197A1 (en) 2023-06-01
CA3172201A1 (en) 2021-09-23
BR112022018682A2 (pt) 2023-02-14
JP2023534779A (ja) 2023-08-14
AU2021236669A1 (en) 2022-11-10
KR20230031814A (ko) 2023-03-07
EP4121110A1 (en) 2023-01-25
WO2021188770A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
Steinberg et al. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma
CR20210500A (es) Anticuerpos de cadena pesada que se unen al psma
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
MX2020009862A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MY185813A (en) Factor xi antibodies and methods of use
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MY166537A (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
MX2020013428A (es) Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana.
MX2021001902A (es) Anticuerpos que se unen a histona 2a y/o 4 citrulinada.
CR20210622A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
NZ602515A (en) Proteins that bind pi16 and uses thereof
WO2019028182A3 (en) TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
MX2021007848A (es) Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
MX2020009879A (es) Anticuerpos anti-il-27 y sus usos.
EA202090922A1 (ru) Композиции и способы истощения cd2+ клеток
MX2021006980A (es) Anticuerpos anti-il-27 y usos de estos.
JOP20220204A1 (ar) الأجسام المضادة لـ cd19 البشرية
MX2021012769A (es) Anticuerpos bloqueadores cd73.
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
MX2022011591A (es) Anticuerpos anti-ceramida.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.
MX2021010254A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.